RecruitingPhase 2NCT07400952

Placebo-controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconus

Multicenter, Randomized, Double-Masked, Placebo-Controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconus


Sponsor

Glaukos Corporation

Enrollment

100 participants

Start Date

Dec 23, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

Multi-center, parallel-group, placebo-controlled trial designed to assess the safety and efficacy of twice-daily topically administered GLK-221 Ophthalmic Solution in subjects with keratoconus.


Eligibility

Min Age: 18 YearsMax Age: 55 Years

Inclusion Criteria2

  • Be ≥ 18 and ≤ 55 years of age
  • Diagnosis of keratoconus in the study eye

Exclusion Criteria2

  • Pregnant, lactating or planning a pregnancy
  • Currently enrolled, or within 30 days prior to Screening were enrolled, in another investigational drug or device trial

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGGLK-221 Ophthalmic Solution

GLK-221 Ophthalmic Solution administered twice daily to both eyes

DRUGPlacebo Ophthalmic Solution

Placebo Ophthalmic Solution administered twice daily to both eyes


Locations(1)

Glaukos Clinical Study Site

Westerville, Ohio, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07400952


Related Trials